Cargando…
Triple versus dual antiplatelet therapy for coronary heart disease patients undergoing percutaneous coronary intervention: A meta-analysis
Coronary heart disease (CHD) is the leading cause of mortality worldwide. Previous studies have suggested that cilostazol-based triple antiplatelet therapy (TAT) may be more effective than conventional dual antiplatelet therapy (DAT) at improving the clinical outcomes of patients with CHD undergoing...
Autores principales: | ZHOU, HONG, FENG, XIAO-LING, ZHANG, HONG-YING, XU, FEI-FEI, ZHU, JIE |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3797250/ https://www.ncbi.nlm.nih.gov/pubmed/24137311 http://dx.doi.org/10.3892/etm.2013.1238 |
Ejemplares similares
-
Meta-analysis of Unguided Deescalation of Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Mohamed, Mohamed M. G., et al.
Publicado: (2022) -
Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome
por: Chen, Shih-Chin, et al.
Publicado: (2014) -
Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions
por: Summaria, Francesco, et al.
Publicado: (2015) -
Shortening Dual Antiplatelet Therapy Duration in High-Risk Patients Undergoing Percutaneous Coronary Intervention
por: Greco, Antonio, et al.
Publicado: (2023) -
Antiplatelet Therapy and Percutaneous Coronary Interventions
por: Davanzo, Rene Hameau, et al.
Publicado: (2021)